Ignite Creation Date:
2024-05-05 @ 6:38 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00523484
Status:
COMPLETED
Last Update Posted:
2010-01-26
First Post:
2007-08-30
Brief Title:
CasodexZoladex Hormonal therApy Study for assessMent of Correlation Between PSA BAI in prOstate Cancer patieNts
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
An Observational Study to Assess Correlation Between Prostate Specific Antigen Beck Anxiety Index in Prostate Cancer Patients Under Hormonal Therapy
Status:
COMPLETED
Status Verified Date:
2010-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CHAMPION
Brief Summary:
This study is an observational study to see whether anxiety level can be correlated with PSA level under the current practice in the patients of prostate cancer taking hormonal therapy For assessment of anxiety level BAIBeck Anxiety Inventory will be used The target population for this study is the patients of prostate cancer diagnosed previously and who are taking hormonal therapy with regular follow-up and PSA test The follow-up duration will be total 6 months with interim visit at 3 month and final visit at 6 month
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None